

**Table 2: Percentage of cytotoxic and targeted chemotherapy agents applied in the 3 lines of treatment (after relapse) and number of cycles received**

<b>Treatment</b>	<b>1st line</b>	<b>2nd line</b>	<b>3rd line</b>	<b>P-value</b>
<b>Conventional (chemotherapy)</b>	154 (86%)	72 (42%)	26-89y	<0.001
<b>Targeted</b>	25 (14%)	99 (58%)	59.5y ± 12.9	
<b>Treatment strategies targeted (associated to chemotherapy):</b>				
Cetuximab	1.1%	9.4%	15.6%	NS
Bevacizumab	13.0%	47.3%	84.4%	
<b>Conventional chemotherapy:</b>				
5FULV	36.3%	0.6%	8.3%	NS
XELOX	25.7%	37.4%	24.0%	
FOLFOX	38.6%	43.3%	47.0%	
FOLFIRI	1.1%	12.9%	5.2%	
FOLFOXIRI	-	16.4%	1.1%	
XELIRI	-	4.7%	34.4%	
<b>Cycles</b>				
≤ 4 cycles	16.8%	15.6%	56.4%	NS
5 - 6 cycles	41.9%	27.4%	-	
7 -8 cycles	19.0%	30.7%	-	
≥ 9 cycles	22.3%	21.8%	-	

5FU/LV = Fluorouracil/Leucovorin, FOLFOX = Fluorouracil, Leucovorin, and Oxaliplatin; XELOX = Capecitabine and Oxaliplatin; FOLFIRI = Irinotecan, Fluorouracil, and Leucovorin, FOLFOXIRI = Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan, XELIRI = Capecitabine and Irinotecan. NS = Non-significant.